A Comparative Analysis of Diabetic Ketoacidosis (DKA) in Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) Users Versus Non-users: A Systematic Review
Abstract
Diabetic ketoacidosis (DKA) remains a life-threatening complication of diabetes mellitus, with emerging concerns about its association with sodium-glucose cotransporter-2 inhibitors (SGLT2i). While SGLT2i offer significant cardiovascular and renal benefits, their potential to increase DKA risk - particularly euglycemic diabetic ketoacidosis (eDKA) - warrants systematic evaluation. This review aims to compare the incidence, clinical features, and outcomes of DKA in SGLT2i users versus non-users. A comprehensive literature search was conducted across PubMed/MEDLINE, Scopus, CINAHL, IEEE Xplore, and Web of Science. Eligible studies included comparative analyses of DKA in SGLT2i users and non-users, with retrospective and prospective designs. Data were extracted on incidence, laboratory features, precipitating factors, and clinical outcomes. Risk of bias was assessed using the Newcastle-Ottawa Scale. Thirteen studies were included, encompassing diverse populations and regions. SGLT2i users exhibited a higher incidence of DKA, with a notable proportion presenting as eDKA. Key distinguishing features included lower blood glucose levels, higher sodium concentrations, and prolonged hospital stays. Surgery and infections were common triggers, while mortality rates remained comparable between groups. Methodological quality was generally high, though heterogeneity precluded meta-analysis. SGLT2i use is associated with an increased risk of DKA, particularly euglycemic variants,…
How strong is the evidence?
Evidence Hub reads this as a systematic review. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.